Regeneron Reports Third Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Regeneron Pharma (REGN) PT Raised to $440 at SunTrust Robinson Humphrey
November 9, 2017 3:47 PM ESTSunTrust Robinson Humphrey analyst Suneja Yatin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $435.00) while maintaining a Hold rating following Q3 results highlighted by Eylea U.S. sales (+3.7% Q/Q), above (+2.1%) consensus.
The firm views near-term catalysts (Dupi in Asthma, anti-PD-1 in CSCC) as already priced-in.
... MoreRegeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... More